“It really depends on the time horizon and, of course, the magic of compounding. If we set aside mega-cap index names (which, let’s be honest, have delivered some jaw-dropping returns and may even feature in our Global SDG Equities strategy), and since cherry picking is the name of the game, I’d highlight two favorites*: Builders FirstSource, a manufacturer and distributor of building products, was among my best investments over a three-year stretch. We started building our position in early 2022, when the market was convinced a housing crash was imminent and sentiment was at rock bottom. Our view was different: we saw a structural housing undersupply, strong demographic tailwinds, and migration to low-tax states as powerful offsets. Builders FirstSource’s dominant market position, improving returns on capital, and clear M&A strategy fueled strong growth and cash flow. As the market rebounded in 2023, our conviction paid off – the stock nearly tripled at its peak.
The other, though more short-term, was Medpace, a Contract Research Organization (CRO) providing outsourced clinical development services. It traded at a very depressed valuation due to cyclical and structural CRO headwinds and weak healthcare sentiment. We concluded that its differentiated full-service model and focus on small to mid-sized biopharma clients make it less exposed to large pharma outsourcing shifts positioning it well for a rebound in biotech funding. Further, Medpace’s profitability, cash flow, disciplined financial management, and a large share buyback program supporting EPS growth made it an attractive candidate for inclusion. Call it luck or skill, but just weeks after we added the name to the strategy, the stock jumped over 50% on results day.”
*These are not buy, sell, or hold recommendations. Holdings are subject to change and shown for illustrative purposes only to demonstrate the strategy as of the stated date. Future inclusion of these securities in the strategy is not guaranteed, nor can their future performance be predicted.